Nodular Lymphoid Hyperplasia as Incidental Finding of Suspect Pulmonary Mass

Hannes Reuter and Stefan Reuter

1Department III of Internal Medicine, University of Cologne, Kerpener Str. 62, Cologne 50937, Germany
2Department of Internal Medicine 4, Klinikum Leverkusen, Am Gesundheitspark 11, Leverkusen 51375, Germany

Correspondences should be addressed to Hannes Reuter; hannes.reuter@uk-koeln.de

Received 4 January 2022; Accepted 6 May 2022; Published 14 May 2022

1.Introduction

Low-grade lymphoid proliferations in the lung, including those with reactive germinal centers, were commonly classified as low-grade B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) [1]. However, Kradin and Mark were first to distinguish a small but distinct subset of lymphoid mass lesions that corresponded histologically to nodular hyperplasia of bronchus-associated lymphoid tissue (BALT) [2]. The unique entity and benign nature of this disorder has subsequently also been recognized by the World Health Organization (WHO), which introduced the term nodular lymphoid hyperplasia (NLH) of the lung [3].

2. Case Presentation

A 64-year-old female presented to the hospital because of suspected traumatic rib injury. She never complained a cough, no fever, weight loss, or night sweats. Chest X-ray did not reveal a fracture but unexpectedly showed a mass in the right upper lobe. This finding was confirmed by computed tomography (CT) showing a solid nodular lesion with irregular margins adjacent to the visceral pleura with a diameter of 1.2 inches in the upper right lobe (Figure 1). Under suspicion of malignancy, a CT-navigated core biopsy (diameter: 0.75 inches) was obtained showing well-defined lymphoid tissue masses with numerous reactive germinal centers, interfollicular lymphocytes, and plasma cells (Figure 2). Immunohistochemically, plasma cells that were reactive for both κ- and λ-light chain immunoglobulins supporting a polyclonal population (Figure 2(c) and 2(d)), and lymphocyte subset markers such as CD20 and CD10 identified B cells, which were negative for Bcl-2 (Figure 2(e)). CD3-positive T cells showed reactive patterns in the interfollicular zone. Ki-67 staining confirmed a high proliferative activity in reactive follicles with no evidence of malignancy (Figure 2(f)). These histological findings could exclude a lymphoma and resulted in the diagnosis of NLH. The postinterventional course was uneventful. A CT of the chest 5 years later confirmed the
benign nature of the tumour with complete regression leaving only a small scar in the area of former lesion.

3. Discussion

The present case underscores the typical immunohistochemical findings and the benign course of NLH, a rare pulmonary disease with morphological features which are highly suggestive of malignancy. The disease was first described by Kradin and Mark in 1983 and is characterized by one or more benign nodules or localized lung infiltrates composed of reactive lymphoid cells [2].

In these mostly asymptomatic patients, the nodules are typically incidental findings in subpleural, occasionally peribronchial location [4]. Large airways involvement is uncommon. If symptoms occur they are unspecific, including cough, dyspnea, and pleuritic pain. Females are slightly more often affected than males in a ratio of 4:3. The age differs largely from 19 to 80 years (median 60 years). Mediastinal or hilar adenopathy is present in approximately one-third of patients [4]. The pathogenesis of NLH is unknown. Song et al. identified NLH in a patient with Sjogren’s syndrome [5] although others did not suggest an association with collagen vascular disease [4].

The lesion is usually detected first in an X-ray or CT from the chest. However, there is no radiographic sign specific for NLH, especially in the distinction to malignant tumours. Based on a series of 67 patients, Fang et al. described the typical radiological manifestations of pulmonary NLH as solitary, or multinodular, solid or subsolid nodules with a wide array of additional radiographic findings, including lobulation, spiculation, vessel convergence, and pleural indentation as well as mediastinal or hilar lymph node involvement [6]. Even in 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), the imaging findings can be very similar to those of lung cancer with varying FDG uptakes [7, 8]. Due to these radiographic signs of malignancy, most patients with NLH primarily undergo surgical lobectomy or sublobular resection of the lung without recurrence [4, 5].

To date, there is only little evidence of spontaneous regression of pulmonary NLH without operation. Some studies reported the regression of remaining lesions following the surgical resection of one nodule [9, 10] and another report described the reduction of an abnormal lung shadow in NLH induced by antibiotic treatment [11]. Surgical resection of NLH is therefore widely accepted not only as a diagnostic but also as a curative measure [6]. However, these patients would experience substantial loss of normal lung parenchyma for a benign condition, especially after complete lobectomy. To our knowledge, the present case is the first description of spontaneous regression of pulmonary NLH after CT-guided needle biopsy supporting an alternative, less invasive, and debilitating diagnostic approach with curative potential.

The histological picture of NLH is characterized by a dense nodular infiltration of mature, polyclonal lymphocytes and plasma cells with multiple reactive germinal centers, sharply demarcated from surrounding parenchyma and with central areas of scarring. Immunohistochemical staining shows a mixture of B cells with polytypic κ- and λ-light chain expression and T cells in the lymphoid infiltrate [4]. These histopathologic features need to be identified in order to distinguish NLH from other neoplasticlymphoproliferative pulmonary lesions. Differential diagnoses include the extranodal MALT lymphoma, which is similarly characterized by a mixed population of lymphoid cells with abundant plasma cells [12–14]. However, while NLH is a polyclonal lymphatic disorder, the MALT lymphoma shows monoclonal tumour cells [4, 15]. In addition, Dutcher bodies and pleural and bronchus invasion are common features of MALT lymphoma. Other low-grade lymphomas such as small lymphocytic lymphoma or chronic lymphocytic leukaemia could mimic NLH as well, but most such cases show a more diffuse infiltrative pattern rather than formation of well-defined nodules. Further differential diagnoses to be considered include the benign/non-neoplastic pulmonary lymphoid disorders such as lymphocytic interstitial pneumonia (LIP), follicular bronchiolitis (FB), or inflammatory
pseudotumour [16–18]. LIP usually shows dense infiltration of plasma cells, lymphocytes, and histiocytes resulting in a diffuse alveolar widening [19]. In addition, the growth pattern is diffuse usually involving the entire lung, rather than nodular in appearance. FB is a lymphoid follicular hyperplasia with germinal centers as well, but can be distinguished from NLH by its location: while NLH is usually located in the subpleural area, and FB is typically distributed along the bronchiolar walls [19]. Some cases may exhibit overlapping features, and the distinction among these entities can be arbitrary. In these cases, the synopsis of clinical, radiographic, and histologic features may help to distinguish between entities.

4. Conclusion

NLH is a benign pulmonary disease with morphological features which are highly suggestive of malignancy. To date, the diagnosis is based on the typical histopathological findings with dense nodular infiltration of mature, polyclonal lymphocytes and plasma cells. Surgical resection of the tumour is the standard diagnostic and therapeutic approach to date, and there was no evidence so far that NLH can regress without operation. The present case shows the spontaneous complete reduction of NLH after CT-guided biopsy highlighting an alternative, less-invasive diagnostic approach with curative potential.
Data Availability
The data are available on request by contacting the corresponding author.

Consent
Written informed consent for publication was obtained from the patient.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this article.

Acknowledgments
The authors express our sincere gratitude to Dr. Rolf Jaussi for providing the histopathological images.

References
[1] P. Isaacson and D. H. Wright, “Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma,” Cancer, vol. 52, no. 8, pp. 1410–1416, 1983.
[2] R. L. Kradin and E. J. Mark, “Benign lymphoid disorders of the lung, with a theory regarding their development,” Human Pathology, vol. 14, no. 10, pp. 857–867, 1983.
[3] E. Brambilla, W. D. Travis, T. V. Colby, B. Corrin, and Y. Shimosato, “The new World Health Organization classification of lung tumours,” European Respiratory Journal, vol. 18, no. 6, pp. 1059–1068, 2001.
[4] S. L. Abbondanzo, W. Rush, K. E. Bijwaard, and M. N. Koss, “Nodular lymphoid hyperplasia of the lung,” The American Journal of Surgical Pathology, vol. 24, no. 4, pp. 587–597, 2000.
[5] M.-K. Song, Y.-M. Seol, Y.-E. Park et al., “Pulmonary nodular lymphoid hyperplasia associated with sjogren’s syndrome,” The Korean Journal of Internal Medicine, vol. 22, no. 3, pp. 192–196, 2007.
[6] L. Fang, J. Xu, L. Wang, Z. He, W. Lv, and J. Hu, “Pulmonary nodular lymphoid hyperplasia: a rare benign disease with malignant mask,” Annals of Translational Medicine, vol. 7, no. 3, p. 43, 2019.
[7] H. Nakamura, K. Miwa, T. Haruki, Y. Adachi, S. Fujioka, and Y. Taniguchi, “Multifocal nodular lymphoid hyperplasia of the lung differently identified by18F-fluorodeoxyglucose positron emission tomography (FDG-PET),” The Thoracic and Cardiovascular Surgeon, vol. 57, no. 07, pp. 439–440, 2009.
[8] U. Yilmaz, I. Unsal, H. Halikolcar et al., “Nodular lymphoid hyperplasia of the lung: the role of positron emission tomography in diagnosis,” Tuberkuloz ve Toraks, vol. 57, pp. 417–421, 2009.
[9] S. Miyoshi, H. Hamada, H. Katayama et al., “A case of pulmonary nodular lymphoid hyperplasia with a resected cavity, followed by spontaneous regression of the remaining lesion,” Internal Medicine, vol. 49, no. 15, pp. 1617–1621, 2010.
[10] S. Kajiwara, S. Sakai, H. Soeda et al., “Multifocal nodular lymphoid hyperplasia of the lung,” Journal of Thoracic Imaging, vol. 20, no. 3, pp. 239–241, 2005.
[11] A. Tanino, Y. Tsubata, S. Hamaguchi, A. Sutani, M. Nagase, and T. Isobe, “Antibiotic-induced reduction of abnormal lung shadow in pulmonary nodular lymphoid hyperplasia,” Respirology Case Reports, vol. 8, no. 2, Article ID e00522, 2020.
[12] H. Béguerot, B. Vergier, M. Parrens et al., “Primary lung small B-cell lymphoma versus lymphoid hyperplasia,” The American Journal of Surgical Pathology, vol. 26, no. 1, pp. 76–81, 2002.
[13] E. Yi and M.-C. Aubry, “Pulmonary pseudoneoplasms,” Archives of Pathology & Laboratory Medicine, vol. 134, no. 3, pp. 417–426, 2010.
[14] M. N. Koss, “Pulmonary lymphoid disorders,” Seminars in Diagnostic Pathology, vol. 12, no. 2, pp. 158–171, 1995.
[15] D. G. Guinee Jr., T. J. Franks, A. J. Gerbino, S. S. Murakami, S. C. Acree, and M. N. Koss, “Pulmonary nodular lymphoid hyperplasia (pulmonary pseudolymphoma),” The American Journal of Surgical Pathology, vol. 37, no. 5, pp. 699–709, 2013.
[16] M. N. Koss, “Malignant and benign lymphoid lesions of the lung,” Annals of Diagnostic Pathology, vol. 8, no. 3, pp. 167–187, 2004.
[17] W. D. Travis and J. R. Galvin, “Rare diseases bullet 13: non-neoplastic pulmonary lymphoid lesions,” Thorax, vol. 56, no. 12, pp. 964–971, 2001.
[18] K.-H. Do, J. S. Lee, J. B. Seo et al., “Pulmonary parenchymal involvement of low-grade lymphoproliferative disorders,” Journal of Computer Assisted Tomography, vol. 29, no. 6, pp. 825–830, 2005.
[19] A. Arcadu, T. Moua, E. Yi, and J. Ryu, “Lymphoid interstitial pneumonitis and other benign lymphoid disorders,” Seminars in Respiratory and Critical Care Medicine, vol. 37, no. 03, pp. 406–420, 2016.